Evidence map›Paper›PMID 31289201›Full record

ArticleHaematologica2020

Mesenchymal stromal cells confer chemoresistance to myeloid leukemia blasts through Side Population functionality and ABC transporter activation.

Laetitia Boutin, Pierre Arnautou, Aurélie Trignol, Amandine Ségot, Thomas Farge, Christophe Desterke, Sabrina Soave, Denis Clay, Emmanuel Raffoux, Jean-Emmanuel Sarry and 4 more

Open access · goldAbstract read
In one paragraph

Article in Haematologica, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 37 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 1 country.

Laetitia BoutinCTSA, IRBA, Clamart.
Pierre ArnautouHematology Department, HIA Percy, Clamart.
Aurélie TrignolCTSA, IRBA, Clamart.
Amandine SégotHematology Department, HIA Percy, Clamart.
Thomas FargeInserm U1037, Cancer Research Center of Toulouse, University of Toulouse, Toulouse.
Christophe DesterkeInserm UMS33, Paul Brousse Hospital, Paris 11 University, Villejuif.
Sabrina SoaveInserm UMR-S-MD1197, Paul Brousse Hospital, Paris 11 University, Villejuif.
Denis ClayInserm UMS33, Paul Brousse Hospital, Paris 11 University, Villejuif.
Emmanuel RaffouxAdult Hematology Department, Saint Louis Hospital, Paris, France.
Jean-Emmanuel SarryInserm U1037, Cancer Research Center of Toulouse, University of Toulouse, Toulouse.
Jean-Valère MalfusonInserm UMR-S-MD1197, Paul Brousse Hospital, Paris 11 University, Villejuif.
Jean-Jacques LatailladeCTSA, IRBA, Clamart.
Marie-Caroline Le Bousse-KerdilèsInserm UMR-S-MD1197, Paul Brousse Hospital, Paris 11 University, Villejuif.
Adrienne AnginotInserm UMR-S-MD1197, Paul Brousse Hospital, Paris 11 University, Villejuif adrienne.anginot@inserm.fr.
Hôpital Paul-Brousse · FRInserm · FRHôpital d'instruction des Armées Percy · FRUniversité Paris-Saclay · FRCentre de Recherche en Cancérologie de Toulouse · FRHôpital Saint-Louis · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Targeting chemoresistant malignant cells is one of the current major challenges in oncology. Therefore, it is mandatory to refine the characteristics of these cells to monitor their survival and develop adapted therapies. This is of particular interest in acute myeloid leukemia (AML), for which the 5-year survival rate only reaches 30%, regardless of the prognosis. The role of the microenvironment is increasingly reported to be a key regulator for blast survival. In this context, we demonstrate that contact with mesenchymal stromal cells promotes a better survival of blasts in culture in the presence of anthracycline through the activation of ABC transporters. Stroma-dependent ABC transporter activation leads to the induction of a Side Population (SP) phenotype in a subpopulation of primary leukemia blasts through alpha (α)4 engagement. The stroma-promoting effect is reversible and is observed with stromal cells isolated from either healthy donors or leukemia patients. Blasts expressing an SP phenotype are mostly quiescent and are chemoresistant

Indexed as

Leukemia, Myeloid, AcuteMesenchymal Stem CellsAnimalsATP-Binding Cassette TransportersDrug Resistance, NeoplasmHumansMiceStromal CellsTumor MicroenvironmentATP-Binding Cassette Transporters

Identifiers

PMID31289201
PMCPMC7109715
OpenAlexW2960758486

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.